CVA21

BIOLOGICAL6 trials

Sponsors

Viralytics, Olivia Newton-John Cancer Research Institute

Conditions

Breast CancerHead and Neck CancerLiver MetastasesMelanomaNon-Small Cell Lung CancerNon-muscle Invasive Bladder CancerProstate CancerUveal Melanoma

Phase 1

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

CompletedNCT00636558

ViralyticsBreast Cancer, Melanoma, Prostate Cancer

Start: 2008-02-29End: 2012-01-12Updated: 2019-07-01

A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)

TerminatedNCT00832559

ViralyticsHead and Neck Cancer

Start: 2009-01-27End: 2011-07-28Updated: 2019-07-19

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

CompletedNCT02316171

ViralyticsNon-muscle Invasive Bladder Cancer

Start: 2015-01-16End: 2016-03-14Updated: 2022-07-27

Pembrolizumab + CVA21 in Advanced NSCLC

Olivia Newton-John Cancer Research InstituteNon-Small Cell Lung Cancer

Start: 2017-08-09End: 2021-10-31Updated: 2021-07-07

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

CompletedNCT03408587

ViralyticsLiver Metastases, Uveal Melanoma

Start: 2018-01-29End: 2019-05-22Updated: 2023-05-06

Phase 2

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

CompletedNCT01636882

ViralyticsMelanoma

Start: 2012-07-03End: 2016-04-06Updated: 2019-07-09

Related Papers

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.

2023-01-1814 citations

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

Journal of Clinical Oncology2021-08-3186 citations

Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.

Journal of Clinical Oncology2016-05-207 citations

Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients

Cancer Research2015-08-015 citations